Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) gapped down prior to trading on Friday. The stock had previously closed at $51.19, but opened at $48.22. Enliven Therapeutics shares last traded at $47.9240, with a volume of 7,297 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ELVN shares. Morgan Stanley started coverage on shares of Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 target price on the stock. The Goldman Sachs Group increased their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Zacks Research upgraded shares of Enliven Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Finally, Barclays began coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $75.44.

Enliven Therapeutics Stock Performance

The business has a 50-day simple moving average of $46.43 and a two-hundred day simple moving average of $43.67. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -28.54 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. Research analysts predict that Enliven Therapeutics, Inc. will post -1.70 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 31,054 shares of company stock valued at $1,493,823. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. KBC Group NV purchased a new position in Enliven Therapeutics during the first quarter worth about $38,000. Three Bridge Wealth Advisors LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter valued at approximately $53,000. State of Wyoming purchased a new stake in Enliven Therapeutics in the 2nd quarter valued at approximately $96,000. Sterling Capital Management LLC increased its position in Enliven Therapeutics by 1,180.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock worth $88,000 after purchasing an additional 1,771 shares during the period. Finally, FNY Investment Advisers LLC acquired a new position in Enliven Therapeutics during the 2nd quarter worth approximately $126,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.